272 related articles for article (PubMed ID: 30658149)
1. Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration.
Zharikov A; Bai Q; De Miranda BR; Van Laar A; Greenamyre JT; Burton EA
Neurobiol Dis; 2019 May; 125():146-153. PubMed ID: 30658149
[TBL] [Abstract][Full Text] [Related]
2. shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model.
Zharikov AD; Cannon JR; Tapias V; Bai Q; Horowitz MP; Shah V; El Ayadi A; Hastings TG; Greenamyre JT; Burton EA
J Clin Invest; 2015 Jul; 125(7):2721-35. PubMed ID: 26075822
[TBL] [Abstract][Full Text] [Related]
3. Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.
Khodr CE; Becerra A; Han Y; Bohn MC
Brain Res; 2014 Mar; 1550():47-60. PubMed ID: 24463035
[TBL] [Abstract][Full Text] [Related]
4. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
[TBL] [Abstract][Full Text] [Related]
5. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
6. Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration.
Van Rompuy AS; Oliveras-Salvá M; Van der Perren A; Corti O; Van den Haute C; Baekelandt V
Mol Neurodegener; 2015 Jun; 10():23. PubMed ID: 26099628
[TBL] [Abstract][Full Text] [Related]
7. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.
St Martin JL; Klucken J; Outeiro TF; Nguyen P; Keller-McGandy C; Cantuti-Castelvetri I; Grammatopoulos TN; Standaert DG; Hyman BT; McLean PJ
J Neurochem; 2007 Mar; 100(6):1449-57. PubMed ID: 17241127
[TBL] [Abstract][Full Text] [Related]
8. Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication.
Flierl A; Oliveira LM; Falomir-Lockhart LJ; Mak SK; Hesley J; Soldner F; Arndt-Jovin DJ; Jaenisch R; Langston JW; Jovin TM; Schüle B
PLoS One; 2014; 9(11):e112413. PubMed ID: 25390032
[TBL] [Abstract][Full Text] [Related]
9. Administration of AAV-Alpha Synuclein NAC Antibody Improves Locomotor Behavior in Rats Overexpressing Alpha Synuclein.
Chen YH; Wu KJ; Hsieh W; Harvey BK; Hoffer BJ; Wang Y; Yu SJ
Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34205689
[TBL] [Abstract][Full Text] [Related]
10. AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo.
Saal KA; Koch JC; Tatenhorst L; Szegő EM; Ribas VT; Michel U; Bähr M; Tönges L; Lingor P
Neurobiol Dis; 2015 Jan; 73():150-62. PubMed ID: 25283984
[TBL] [Abstract][Full Text] [Related]
11. Cre-dependent AAV vectors for highly targeted expression of disease-related proteins and neurodegeneration in the substantia nigra.
Grames MS; Dayton RD; Jackson KL; Richard AD; Lu X; Klein RL
FASEB J; 2018 Aug; 32(8):4420-4427. PubMed ID: 29513569
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease.
Albert K; Voutilainen MH; Domanskyi A; Piepponen TP; Ahola S; Tuominen RK; Richie C; Harvey BK; Airavaara M
J Neurosci Res; 2019 Mar; 97(3):346-361. PubMed ID: 30548446
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
14. Inclusion of a portion of the native SNCA 3'UTR reduces toxicity of human S129A SNCA on striatal-projecting dopamine neurons in rat substantia nigra.
Khodr CE; Pedapati J; Han Y; Bohn MC
Dev Neurobiol; 2012 Jun; 72(6):906-17. PubMed ID: 22021082
[TBL] [Abstract][Full Text] [Related]
15. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
Coune PG; Bensadoun JC; Aebischer P; Schneider BL
J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
[TBL] [Abstract][Full Text] [Related]
16. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
[TBL] [Abstract][Full Text] [Related]
17. Modelling cognitive deficits in Parkinson's disease: Is CA2 a gateway for hippocampal synucleinopathy?
Cinar E; Yalcin-Cakmakli G; Saka E; Ulusoy A; Yuruker S; Elibol B; Tel BC
Exp Neurol; 2020 Aug; 330():113357. PubMed ID: 32437708
[TBL] [Abstract][Full Text] [Related]
18. An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons.
Khodr CE; Sapru MK; Pedapati J; Han Y; West NC; Kells AP; Bankiewicz KS; Bohn MC
Brain Res; 2011 Jun; 1395():94-107. PubMed ID: 21565333
[TBL] [Abstract][Full Text] [Related]
19. FOXO3 determines the accumulation of α-synuclein and controls the fate of dopaminergic neurons in the substantia nigra.
Pino E; Amamoto R; Zheng L; Cacquevel M; Sarria JC; Knott GW; Schneider BL
Hum Mol Genet; 2014 Mar; 23(6):1435-52. PubMed ID: 24158851
[TBL] [Abstract][Full Text] [Related]
20. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.
Koprich JB; Johnston TH; Huot P; Reyes MG; Espinosa M; Brotchie JM
PLoS One; 2011 Mar; 6(3):e17698. PubMed ID: 21408191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
